ClinicalTrials.gg
RecruitingNCT06276257Updated Mar 19, 2026

Paravertebral Block for Mastectomy With Immediate Reconstruction

An interventional study of Paravertebral block and Usual analgesia in Postoperative Pain, sponsored by CHU de Quebec-Universite Laval. Recruiting at 1 site in Canada. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by CHU de Quebec-Universite Laval · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 190 studies in Pain, Postoperative with a site in Canada — 38 open to participants now, 42 under way, 3 of them phase 3. Pain, Postoperative · Canada.

Planned enrollment
109th of 175
60 · median 82
Started
2024
with 10 others
No phase
94 of 190
17 open now
Primary completion
2026-12
later than 22 of 41 live
Registered
167th of 190
by date

Among the 190 studies in Pain, Postoperative with a site in Canada, this one is the 109th largest by planned enrollment of the 175 interventional ones that give a count, is one of 11 that started in 2024, is one of 94 with no phase, reaches primary completion later than 22 of the 41 other live ones, and was the 167th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

38 of the 190 studies in Pain, Postoperative with a site in Canada are open now. Recruiting first, the newest first:

32 more — sign in →

All 38 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 190 studies in Pain, Postoperative with a site in Canada, or all of them as a file.
02

Study summary

Following a mastectomy, patients may develop chronic pain, called post-mastectomy pain syndrome (PMPS). This syndrome manifests itself as complex neuropathic pain that seems linked to nerve damage suffered either during surgery, during healing or by nervous system dysfunction. However, the exact pathophysiology remains unknown. Typically, the pain is located on the ipsilateral side of the surgery and projects to the anterior thorax to the lateral thorax and may affect the proximal part of the arm. This pain persists for more than three months following the procedure and has the characteristics of neuropathic pain: burning sensation, tingling, electric shock, hyperalgesia, etc. The prevalence of PMDS varies between 2% and 78%; this disparity comes from the fact that there are no clear criteria in the literature for making the diagnosis. One of the risk factors for developing PMDS is the presence of acute pain immediately postoperatively.

The main objective of this study is to compare two analgesic modalities, namely BPV (study modality) and usual analgesia (control modality), in patients undergoing total mastectomy with immediate reconstruction under general anesthesia with the aim of to evaluate their functional pain score at 24, 48 and 72 hours following the surgical procedure.

03

Conditions studied

  • Postoperative Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-70 years of age
  • woman scheduled for unilateral mastectomy with immediate reconstruction

Exclusion criteria

Exclusion Criteria:

  • Patients who will have an axillary dissection during surgery.
  • Woman with severe hepatic insufficiency ( Classification B and above24).
  • Woman with kidney failure stage 4 and above25.
  • (BMI) > 40 kg/m2.
  • Woman with an allergy to local anesthetics.
  • Woman with a bleeding disorder in whom BPV is .
  • Woman in whom stopping antiplatelet or anticoagulant therapy does not allow compliance with the standards of practice of neuraxial anesthesia issued by the American Society of Regional Anesthesia.
  • Woman with a single lung.
  • Pregnant woman.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Paravertebral block

    Preoperative paravertebral block on the side of mastectomy in addition to usual analgesia.

    Procedure: Paravertebral block

  • Active comparator
    Usual analgesia

    Usual analgesia, as per anesthesiologist's preferences.

    Procedure: Usual analgesia

Interventions

  • ProcedureParavertebral block

    An ultrasound-guided technique will be used to inject a volume of 40 mL of ropivacaine 0.2%, up to a maximum of 1.5 mg/kg, into the paravertebral space between the T3 and T4 vertebrae.

  • ProcedureUsual analgesia

    The patient will receive analgesia as per the anesthesiologist's preferences.

06

What researchers measure

Primary outcomes

  1. Evaluation of postoperative pain using the BPI

    Postoperative pain will be measured using the Brief Pain Inventory (BPI)

    Time frame: 24 hours, 28 hours, 72 hours after surgery

Secondary outcomes

  1. Total use of opioids received intraoperatively.

    Total dose of narcotics received intraoperatively (in mg morphine equivalent)

    Time frame: within 3 months after surgery

  2. Use of non-opioid analgesia intraoperatively

    Analgesics other than opioids used intraoperatively

    Time frame: During surgery

  3. Total dose of opioids received in the PACU

    Total dose of narcotics received in the post-anesthesia care unit (PACU) (in mg morphine equivalent)

    Time frame: During PACU stay

  4. Time before first opioid

    Time to first opioid dose after surgery

    Time frame: Within 3 months after surgery

  5. Total opioids consumed in the 48 hours following surgery

    Total quantity of opioids consumed in the 48 hours following surgery (in morphine equivalent)

    Time frame: Within 48 hours after surgery

  6. Chronic pain

    Presence of chronic pain at the surgical site at 3 months

    Time frame: At 3 months after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 28 months is above that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2024
First posted
Feb 23, 2024
StartActual
Aug 5, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06276257
Responsible party
Sponsor
First posted
Feb 23, 2024
Start date
Aug 5, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Mar 19, 2026

Study contacts

Jean-Charles Hogue
Contact
jean-charles.hogue@crchudequebec.ulaval.ca
418-525-4444

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion